The world of wearable technology is booming, with a market now worth more than $63 billion. From fitness trackers to smartwatches, these devices are no longer just about counting steps or tracking calories. They increasingly provide insights into heart rate, sleep cycles, blood oxygen, and even blood pressure. This shift is blurring the line between consumer wellness products and regulated medical devices, creating mounting pressure on the U.S. Food and Drug Administration (FDA).
Wearables are not new. As far back as the 1940s, Holter monitors tracked heart activity in patients. What has changed is accessibility. Today’s wearables are mass-market devices worn daily by millions. Companies like Apple, Fitbit, and WHOOP market them as lifestyle tools, but many features edge into medical territory.
The FDA typically determines regulation based on a product’s “intended use.” If a company claims its device can diagnose, monitor, or treat a condition, it may be subject to medical device oversight. However, the explosion of health-focused features has made this framework increasingly difficult to enforce. Recently, the FDA issued a warning to WHOOP over its blood pressure claims, a sign of rising regulatory scrutiny. One industry expert likened the current environment to the “wild, wild West,” with innovation outpacing clear rules.
Looking ahead, the FDA faces a major challenge: how to protect consumers without stifling innovation. Overregulation could slow down promising advances, while under-regulation could risk patient safety. As more wearable devices inch closer to providing clinically meaningful data, the agency will need new policies and deeper expertise. The balance the FDA strikes will shape the future of wearable health technology—and determine how these tools are trusted in both the wellness and medical space.
